Namocell Inc.

4 articles about Namocell Inc.

• BIO-TECHNE ANNOUNCES COMPLETION OF NAMOCELL ACQUISITION

  7/5/2022

  Bio-Techne Corporation (NASDAQ:TECH), today announced it has completed the acquisition of Namocell, Inc.

• BIO-TECHNE TO ACQUIRE NAMOCELL

  6/22/2022

  Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Namocell, Inc.

• HepaTx, Namocell, and Takara Bio USA complete second phase of collaboration on single cell analysis for cell therapy to treat late-stage liver diseases

  3/12/2021

  HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells differentiated from adipose tissue-derived stromal cells using Namocell's Single Cell Dispensers and Takara Bio's SMART-seq® kits to characterize HepaTx's novel cell therapies for liver disease.

• Namocell, Takara Bio USA and HepaTx collaborate on single cell genomics analysis for cell therapy to treat late-stage liver diseases

  2/20/2020

  Namocell Inc. announced that it has entered into a collaboration with Takara Bio and HepaTx to use Namocell's Single Cell Dispensers to perform single cell isolation on HepaTx's unique hepatocyte-like cells developed from adipose tissue-derived stromal cells, and characterize them by single cell RNA-seq using Takara Bio's SMART-Seq technology.